These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35677634)

  • 1. Abnormal Expression of N6-Methyladenosine RNA Methylation Regulator IGF2BP3 in Colon Cancer Predicts a Poor Prognosis.
    Wu T; Zhang X; Xing L; Pan D; Liu P; Ding R; Yang R; Yang X; Li Y
    Dis Markers; 2022; 2022():5883101. PubMed ID: 35677634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer.
    Yang Z; Wang T; Wu D; Min Z; Tan J; Yu B
    J Exp Clin Cancer Res; 2020 Sep; 39(1):203. PubMed ID: 32993738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma.
    Ji J; Liu S; Liang Y; Zheng G
    BMC Genom Data; 2023 Aug; 24(1):44. PubMed ID: 37568073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas.
    Sun C; Zheng X; Sun Y; Yu J; Sheng M; Yan S; Zhu Q; Lan Q
    Front Genet; 2021; 12():743738. PubMed ID: 34721530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impact of
    Guo W; Huai Q; Wan H; Guo L; Song P; Gao S; He J
    DNA Cell Biol; 2021 Feb; 40(2):316-331. PubMed ID: 33493403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer.
    Chen S; Li X; Guo L; Zhang J; Li L; Wang X; Zhu Y; Wang J
    J BUON; 2021; 26(5):1931-1941. PubMed ID: 34761602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of m
    Liu T; Li H; Du G; Ma J; Shen J; Zhao H; Luo F; Li H
    Gene; 2022 May; 821():146250. PubMed ID: 35151825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
    BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting IGF2BP3 in Cancer.
    Liu X; Chen J; Chen W; Xu Y; Shen Y; Xu X
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA.
    Fan J; Zhuang M; Fan W; Hou M
    PeerJ; 2023; 11():e15706. PubMed ID: 37663284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of m
    Kuai D; Zhu S; Shi H; Yang R; Liu T; Liu H; Min L; Zhang S
    Life Sci; 2021 May; 273():119258. PubMed ID: 33636176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGF2BP3 is an essential N
    Xu X; Cui J; Wang H; Ma L; Zhang X; Guo W; Xue X; Wang Y; Qiu S; Tian X; Miao Y; Wu M; Yu Y; Xu Y; Wang J; Qiao Y
    Mater Today Bio; 2022 Dec; 17():100503. PubMed ID: 36457846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Interferon Gamma-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Xie Y
    Front Oncol; 2022; 12():876660. PubMed ID: 35747790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prognostic Model Based on the Immune-related Genes in Colon Adenocarcinoma.
    Sun YL; Zhang Y; Guo YC; Yang ZH; Xu YC
    Int J Med Sci; 2020; 17(13):1879-1896. PubMed ID: 32788867
    [No Abstract]   [Full Text] [Related]  

  • 17. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent.
    Wang X; Tian L; Li Y; Wang J; Yan B; Yang L; Li Q; Zhao R; Liu M; Wang P; Sun Y
    J Exp Clin Cancer Res; 2021 Feb; 40(1):80. PubMed ID: 33637103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
    Cai J; Zhou M; Xu J
    World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients.
    Zhang P; Liu G; Lu L
    Front Cell Dev Biol; 2021; 9():703629. PubMed ID: 34336856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The YTH Domain Family of N6-Methyladenosine "Readers" in the Diagnosis and Prognosis of Colonic Adenocarcinoma.
    Xu D; Shao J; Song H; Wang J
    Biomed Res Int; 2020; 2020():9502560. PubMed ID: 32596399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.